These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 12975495

  • 1. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells.
    Stover T, Kester M.
    J Pharmacol Exp Ther; 2003 Nov; 307(2):468-75. PubMed ID: 12975495
    [Abstract] [Full Text] [Related]

  • 2. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
    Stover TC, Sharma A, Robertson GP, Kester M.
    Clin Cancer Res; 2005 May 01; 11(9):3465-74. PubMed ID: 15867249
    [Abstract] [Full Text] [Related]

  • 3. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.
    Stover TC, Kim YS, Lowe TL, Kester M.
    Biomaterials; 2008 Jan 01; 29(3):359-69. PubMed ID: 17964645
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
    Tran MA, Smith CD, Kester M, Robertson GP.
    Clin Cancer Res; 2008 Jun 01; 14(11):3571-81. PubMed ID: 18519791
    [Abstract] [Full Text] [Related]

  • 8. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo.
    Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE.
    Drug Metab Dispos; 2008 Aug 01; 36(8):1709-15. PubMed ID: 18490436
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA, Gomes-da-Silva LC, Moura V, Simões S, Moreira JN.
    J Control Release; 2014 Dec 28; 196():122-31. PubMed ID: 25305563
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
    Chintalapati M, Truax R, Stout R, Portier R, Losso JN.
    J Agric Food Chem; 2009 Jun 24; 57(12):5201-10. PubMed ID: 19476359
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High ceramide content liposomes with in vivo antitumor activity.
    Shabbits JA, Mayer LD.
    Anticancer Res; 2003 Jun 24; 23(5A):3663-9. PubMed ID: 14666662
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development and use of ceramide nanoliposomes in cancer.
    Watters RJ, Kester M, Tran MA, Loughran TP, Liu X.
    Methods Enzymol; 2012 Jun 24; 508():89-108. PubMed ID: 22449922
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 24; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 18. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.
    Shabbits JA, Mayer LD.
    Biochim Biophys Acta; 2003 May 02; 1612(1):98-106. PubMed ID: 12729935
    [Abstract] [Full Text] [Related]

  • 19. PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery.
    Zou P, Stern ST, Sun D.
    Pharm Res; 2014 Mar 02; 31(3):684-93. PubMed ID: 24065591
    [Abstract] [Full Text] [Related]

  • 20. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D, Garg A, Kokkoli E.
    Langmuir; 2008 Dec 02; 24(23):13518-24. PubMed ID: 18954096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.